BioSpace News Archive

Conformis, Inc. announced the strong results of a published retrospective study of procedures using Conformis’ patient-specific iTotal® CR knee replacement implant, which assessed implant survivorship, patient satisfaction, and functional outcomes.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351 in Chinese patients with solid tumors (ClinicalTrials.gov, NCT05005234) completed dosing of the first subject.

Pulmotect reported positive topline results from their randomized, placebo-controlled Phase-2 trial of PUL-042 against COVID-19. Patients treated with inhaled PUL-042 had a statistically significant reduction in the time to improvement of the combined respiratory symptoms of cough and shortness of breath.

Ajax Therapeutics, Inc. today announced the company has expanded its leadership team

BIOTRONIK announced today it received U.S. Food and Drug Administration (FDA) approval of its Orsiro® Mission bioabsorbable polymer drug-eluting stent system (BP-DES).

Curemark, LLC announced the appointment of Afia Asamoah to its Board of Directors, effective immediately. She is currently Head of Legal for the health business unit of Google.

enlightenVue, Inc. announced today that the first patient was successfully enrolled and treated as part of a clinical trial using its 510(k) cleared, single-use micro-endoscope.

Sommetrics, a private company developing products and services to improve sleep health, today announced the launch of the pivotal clinical trial of its aerSleep® II device for the treatment of obstructive sleep apnea (OSA).

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the national launch of its RediTrex® line of pre-filled syringes designed for the safe and simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.